Abstract

Drug molecules not only interact with specific targets, but also alter the state and function of the associated biological network. How to design drugs and evaluate their functions at the systems level becomes a key issue in highly efficient and low–side-effect drug design. The arachidonic acid metabolic network is the network that produces inflammatory mediators, in which several enzymes, including cyclooxygenase-2 (COX-2), have been used as targets for anti-inflammatory drugs. However, neither the century-old nonsteriodal anti-inflammatory drugs nor the recently revocatory Vioxx have provided completely successful anti-inflammatory treatment. To gain more insights into the anti-inflammatory drug design, the authors have studied the dynamic properties of arachidonic acid (AA) metabolic network in human polymorphous leukocytes. Metabolic flux, exogenous AA effects, and drug efficacy have been analyzed using ordinary differential equations. The flux balance in the AA network was found to be important for efficient and safe drug design. When only the 5-lipoxygenase (5-LOX) inhibitor was used, the flux of the COX-2 pathway was increased significantly, showing that a single functional inhibitor cannot effectively control the production of inflammatory mediators. When both COX-2 and 5-LOX were blocked, the production of inflammatory mediators could be completely shut off. The authors have also investigated the differences between a dual-functional COX-2 and 5-LOX inhibitor and a mixture of these two types of inhibitors. Their work provides an example for the integration of systems biology and drug discovery.

Highlights

  • Nonsteriodal anti-inflammatory drugs (NSAIDs) are widely used for the treatment of musculoskeletal pain and other conditions

  • To assist the design of safe anti-inflammatory drugs, we have constructed a computational model of the arachidonic acid (AA) metabolic network in human polymorphous leukocytes

  • By analyzing the flux changes upon drug treatment in this metabolic network, drugs against multiple targets were found to be capable of reducing toxicity as they exhibited balanced control of the system

Read more

Summary

Introduction

Nonsteriodal anti-inflammatory drugs (NSAIDs) (e.g., aspirin) are widely used for the treatment of musculoskeletal pain and other conditions. NSAIDs do alleviate the aches and pains, these drugs have undesirable side effects on the gastrointestinal tract and the central nervous system in addition to the potential exacerbation of conditions such as asthma [1]. The findings that cyclooxygenase-2 (COX-2) plays a major role in inflammation, and that inhibition of COX-1 causes gastrointestinal toxicity and mild bleeding diathesis [3], had suggested that selective COX-2 inhibitor would be an effective anti-inflammatory drug with low gastrointestinal side effects [4]. The unexpected cardiovascular side effects of selective COX-2 inhibitors have surfaced [5,6]. Safe anti-inflammatory drug design remains a great challenge

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call